Woodline Partners LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Woodline Partners LP boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 124.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 423,828 shares of the specialty pharmaceutical company’s stock after buying an additional 235,257 shares during the quarter. Woodline Partners LP owned approximately 0.77% of Supernus Pharmaceuticals worth $15,326,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Barclays PLC lifted its stake in Supernus Pharmaceuticals by 88.3% in the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock valued at $3,393,000 after buying an additional 51,005 shares in the last quarter. Empowered Funds LLC purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $1,498,000. Smartleaf Asset Management LLC lifted its stake in Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 870 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in Supernus Pharmaceuticals by 6.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company’s stock worth $2,169,000 after purchasing an additional 3,495 shares in the last quarter. Finally, Norges Bank purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $4,540,000.

Analysts Set New Price Targets

A number of research firms have weighed in on SUPN. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $32.63 on Thursday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The firm has a 50 day moving average price of $31.98 and a 200 day moving average price of $34.80. The company has a market capitalization of $1.83 billion, a PE ratio of 30.50 and a beta of 0.74.

Insider Activity at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.